| Advanced Breast Cancer Therapies | Lifetime | 5 | DE 1 | 99.92 |
| Breast Cancer Treatment Studies | Lifetime | 7 | DE 1 | 99.95 |
| Cancer Treatment and Pharmacology | Lifetime | 15 | DE 2 | 99.92 |
| HER2/EGFR in Cancer Research | Lifetime | 10 | DE 1 | 99.92 |
| Peptidase Inhibition and Analysis | Lifetime | 90 | DE 8 | 99.54 |
| Protease and Inhibitor Mechanisms | Lifetime | 66 | DE 5 | 99.25 |
| Cancer Cells and Metastasis | Lifetime | 223 | DE 15 | 98.89 |
| Cancer Genomics and Diagnostics | Lifetime | 394 | DE 20 | 99.26 |
| Breast Lesions and Carcinomas | Lifetime | 100 | DE 6 | 99.08 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 597 | DE 36 | 98.99 |
| Cancer-related Molecular Pathways | Lifetime | 295 | DE 9 | 98.92 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 549 | DE 26 | 98.78 |
| BRCA gene mutations in cancer | Lifetime | 223 | DE 9 | 98.25 |
| Economic and Financial Impacts of Cancer | Lifetime | 229 | DE 3 | 97.28 |
| Neutropenia and Cancer Infections | Lifetime | 285 | DE 29 | 97.44 |
| Estrogen and related hormone effects | Lifetime | 856 | DE 26 | 97.21 |
| Colorectal Cancer Treatments and Studies | Lifetime | 993 | DE 45 | 97.27 |
| Biosimilars and Bioanalytical Methods | Lifetime | 271 | DE 19 | 95.48 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 602 | DE 61 | 95.82 |
| Cancer-related cognitive impairment studies | Lifetime | 244 | DE 10 | 94.71 |
| Brain Metastases and Treatment | Lifetime | 843 | DE 72 | 95.17 |
| Blood disorders and treatments | Lifetime | 819 | DE 66 | 92.38 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 523 | DE 16 | 91.55 |
| Male Breast Health Studies | Lifetime | 372 | DE 21 | 72.76 |
| Breast Cancer Treatment Studies | 2021-2025 | 3 | DE 1 | 99.98 |
| Cancer Treatment and Pharmacology | 2021-2025 | 6 | DE 1 | 99.90 |
| Cancer-related Molecular Pathways | 2021-2025 | 3 | DE 1 | 99.56 |
| Advanced Breast Cancer Therapies | 2021-2025 | 7 | DE 1 | 99.90 |
| HER2/EGFR in Cancer Research | 2021-2025 | 7 | DE 2 | 99.89 |
| Cancer-related cognitive impairment studies | 2021-2025 | 5 | DE 1 | 97.59 |
| Cancer Cells and Metastasis | 2021-2025 | 51 | DE 5 | 97.47 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 276 | DE 7 | 98.95 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 183 | DE 14 | 97.82 |
| Breast Lesions and Carcinomas | 2021-2025 | 48 | DE 5 | 96.83 |
| Cancer Genomics and Diagnostics | 2021-2025 | 526 | DE 34 | 96.63 |
| Estrogen and related hormone effects | 2021-2025 | 69 | DE 2 | 94.43 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 328 | DE 18 | 94.59 |
| BRCA gene mutations in cancer | 2021-2025 | 245 | DE 9 | 92.74 |
| Brain Metastases and Treatment | 2021-2025 | 291 | DE 38 | 92.34 |
| Global Cancer Incidence and Screening | 2021-2025 | 631 | DE 10 | 91.26 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 775 | DE 17 | 83.54 |
| Cancer Risks and Factors | 2021-2025 | 865 | DE 28 | 75.56 |
| Advances in Oncology and Radiotherapy | 2021-2025 | 848 | DE 35 | 70.12 |
